About this trial
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.
The aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.
Describing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.
Eligibility criteria
Qualifiers
Age 18 or over
Consultant in an infectious diseases department
Have given written consent to participate in the study
Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.
Disqualifiers
- Pregnant and breast-feeding women
Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)
Participants who are not fluent in French and who do not have a support person capable of reading French.
Persons unable to express their consent.
Trial design
Treatments tested in this trial
- Peripheral venous blood sample
Treatment groups
Sponsors and collaborators
University Hospital, Montpellier
Lead sponsor
TransVIHMI UM, IRD UMI233, Inserm U1175
Collaborator
UMR 1058 Pathogenesis & Control of Chronic & Emerging Infections PCCEI
Collaborator